The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.

@article{Griffiths2017TheES,
  title={The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.},
  author={Christopher Griffiths and Diamant Thaçi and Sascha Gerdes and Peter Arenberger and Grażyna Pulka and K{\"u}lli Kingo and Jolanta Weglowska and N Hattebuhr and Johann A Poetzl and Heike Woehling and Guido Wuerth and M. Afonso},
  journal={The British journal of dermatology},
  year={2017},
  volume={176 4},
  pages={928-938}
}
BACKGROUND GP2015 is a proposed etanercept biosimilar. OBJECTIVES To demonstrate equivalent efficacy, and comparable safety and immunogenicity of GP2015 and the etanercept originator (ETN, Enbrel® ) in patients with moderate-to-severe chronic plaque-type psoriasis. METHODS In total, 531 eligible patients were randomized 1 : 1 to self-administer GP2015 or ETN twice weekly subcutaneously. Patients with ≥ 50% improvement in Psoriasis Area and Severity Index (PASI 50) at week 12 were… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Similar Papers

Loading similar papers…